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Background: Metastases from breast cancer cause the frequent involvement of lung, bone, liver, and brain, while
the occurrence of metastases to the gastrointestinal tract is rare, and more frequently discovered after a primary
diagnosis of breast cancer. Solitary pancreatic metastases from breast cancer, without widespread disease, are
actually unusual, and only 19 cases have been previously described; truly exceptional is a solitary pancreatic
metastasis becoming evident together with the primary breast cancer.
Case presentation: A 68-year-old woman reported general fatigue, lethargy, and jaundice. Abdominal ultrasound
(US) and magnetic resonance imaging (MRI) showed an ampulloma of Vater’s papilla; moreover, a neoplastic nodule
in the left breast was diagnosed. She underwent surgery for both breast cancer and ampulloma of Vater’s papilla.
Pathological examination of pancreatic specimen, however, did not confirm primary carcinoma of the duodenal
papilla, but showed a metastatic involvement of pancreas from lobular breast cancer. Immunohistochemistry has
been essential to confirm the origin of the malignancy: hormone receptors and mammaglobin were expressed in
both the primary breast tumor and the pancreatic metastasis.
Conclusions: This is one of the few reported cases in literature of an isolated and synchronous pancreatic
metastasis from breast cancer, where the definitive diagnosis was obtained only after surgery. We discuss the
controversies in this diagnosis and the choice of correct treatment. The surgical resection of solitary metastases can
be performed in the absence of disseminated disease.
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Breast cancer is the most common malignancy in
women [1,2] and metastatic spread causes frequent
involvement of lung, bone, liver, and brain [3]. The oc-
currence of metastases from breast cancer to the gastro-
intestinal tract and to the pancreas is rare, and more
frequently discovered after a primary diagnosis of breast
cancer [4,5]. Metastatic spread to the pancreas from
different primary is unusual and accounts for appro-* Correspondence: nando.riccardi@alice.it
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reproduction in any medium, provided the orximately 2% of pancreatic malignancies [6,7], while
metastatic involvement of pancreas from primary breast
cancer is a rare event. In a large autopsy series, the
prevalence of pancreatic metastases has been described
to be as high as 6% to 11% [8-10]. Although many pa-
tients with pancreatic metastases have widespread dis-
ease, isolated metastases to the pancreas can be found
[11]. If the metastatic involvement of pancreas from
breast cancer is unusual, detection of isolated and syn-
chronous pancreatic metastasis is a really exceptional
event, and when an isolated metastasis in the pancreas
becomes symptomatic, it is often misdiagnosed asLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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development of imaging modalities, the preoperative
diagnosis of pancreatic malignancy is still suboptimal.
Image-guided fine-needle aspiration (FNA) is an accur-
ate and safe method for evaluating pancreatic lesions,
without open biopsy or laparotomy. Here we present
one of the few reported cases of synchronous and soli-
tary metastasis to the head of the pancreas from lobular
breast cancer, with the purpose to review the clinical
presentation, the diagnostic procedures, and therapeutic
management.
Case presentation
In May 2012 a 68-year-old woman complaining of gen-
eral fatigue, lethargy, and jaundice presented to the
Emergency Unit of Cardarelli Hospital. Biochemical
tests revealed hyperglycemia (483 mg/dl), elevated total
bilirubin (4.22 mg/dl, with conjugated bilirubin of
3.49 mg/dl), high levels of CA 15.3 (320.6 UI/mL), and
CA 19.9 (490.7 UI/mL), while levels of CEA and CA125
were within normal limits. Abdominal ultrasonography
(US) showed biliary sludge and bile duct dilation, and
magnetic resonance imaging (MRI) with cholangiog-
raphy confirmed an enlargement of extra-hepatic bile
ducts (14 mm in diameter) evident until the upper papil-
lary tract, where a stop of the signal suggested a tumor
of the duodenal papilla (Figure 1). Blurring of the uncin-
ate process of the pancreas and several lymph adenopa-
thies were reported. In a few days the jaundice increased
and biochemical tests underlined a liver dysfunction
(GOT 200 UI/L, GPT 238 UI/L, ALP 320 UI/L, GGT
1,441 UI/L, and cholinesterase 2,540 UI/L). Moreover,Figure 1 CT scan at the diagnosis. Contrast CTscan of the
abdomen demonstrating an enlargement of the common bile duct
(14 mm in diameter, see black arrow) and of the of the gallbladder
with an inhomogeneous material into the lumen compatible with
biliary sludge and microlithiasis. The extra-hepatic bile ducts swelling
was evident until the upper papillary tract.during the diagnostic procedures, a mammary US re-
vealed a hypoechoic nodule of 25 mm of the left breast
with fringed margins. After mammography with FNAC
describing a 30 mm breast carcinoma in the left breast
(Figure 2), she was admitted at our department of
General Surgery and Breast Unit, with a diagnosis of pri-
mary breast cancer and primary carcinoma of the duo-
denal papilla. Total body CTscan confirmed the previous
findings and didnot show other secondary involvements.
An ERCP showed an ulcerate papilla, assuming the
lesion as an ampulloma, but biopsies were not signifi-
cant for diagnosis.
In June the patient underwent one-time surgery for
both breast cancer and ampulloma of Vater’s papilla.
During the pancreatic time the gland showed features of
infiltrations and intraoperative Trucut biopsies were per-
formed; the confirmation of the presence of poorly dif-
ferentiated carcinoma suggestive for pancreatic origin
allowed us to perform Whipple’s procedure. The breast
time consisted of Patey’s mastectomy for an invasive
lobular carcinoma localized in the upper inner left
quadrant, measuring 3.2 cm at its longest dimension.
None of the 14 axillaries lymph nodes removed were
malignant.
Pathological examination of the pancreatic mass re-
vealed a lesion of 2.5 cm infiltrating the ampulla and the
perivisceral adipose tissue, but surprisingly did not con-
firm primary adenocarcinoma of the pancreas: micro-
scopic features consisted of a metastatic lobular
carcinoma of the breast (Figure 3). Surgical margins of
the pancreatic resection were free from neoplastic infil-
tration as were the isolated lymph nodes.
Breast specimen confirmed a grade II invasive lobular
carcinoma (Figure 4) exhibiting high levels of estrogen
(90%) and progesterone receptors (80%), HER2-negative,
ki-67 = 20%. Because of the rarity of metastases to the
pancreas from breast cancer, a specific immunohysto-
chemical panel was performed to confirm the origin.
Mammoglobin was positive, hormone receptors were
highly expressed, both in the breast and the pancreatic
tumors, confirming secondary pancreatic involvement
from lobular carcinoma.
The breast tumor board planned a first-line hormonal
therapy for advanced disease with Letrozol, on an out-
patient basis. Cytotoxic chemotherapy was not pre-
scribed, while radiotherapy was not indicated. Twelve
months after the operation, the patient is alive without
evidence of distant metastasis confirmed by total body
computed tomography (CT) scan.
Discussion
Clinical presentation
The metastatic involvement of the pancreas is most
often related to other intra-abdominal malignancies [7],
Figure 2 Left mammogram. A nodule with irregular margins revealed in the left breast.
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tric cancer [12,13]. A report of 1,000 autopsied cases has
revealed that for breast cancer the metastatic pancreatic
involvement is a rare occurrence ranking at approxi-
mately 6% to 11% of all malignancies [5,14]. MetastaticFigure 3 Histological features of pancreatic mass. (a) Small disaggrega
×100). (b) Immunohistochemical staining of ER in the pancreatic head masinvolvement of the pancreas from primary breast cancer
as solitary metastasis sites has an incidence lower than
3%: the literature reflects the rarity of this clinical sce-
nario with 23 published reports of solitary pancreatic
metastases originating from breast cancer (Table 1).ted tumor cells infiltrating the pancreatic parenchyma (H&E staining,
s (×250).
Figure 4 Histological features of breast carcinoma. (a) Breast lobular carcinoma (H&E staining, ×250). (b) Immunohistochemical staining of ER
in the breast lobular carcinoma (×250).
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metachronous, sometimes occurring very late. Literature
describes an interval time from the first diagnosis and
recurrence varies from a few months to several years
and considers the synchronous presentation as an ex-
tremely rare finding [33]. Cancer metastatic to the pan-
creas usually develops late in the course of the disease
and is associated usually with widespread metastases
[34,35]. Although pancreatic metastases may clinically
mimic primary pancreatic adenocarcinoma [36,37], most
patients (50% to 83%) with pancreatic metastases are
completely asymptomatic and the pancreatic mass is
detected on routine follow-up examination [38,39].
Therefore, the presenting symptoms of these specific
metastases are not necessarily distinguishable from other
types of pancreatic cancer, but the diagnosis should be
considered in any patient with a pancreatic mass and a
history of breast cancer [40].Diagnosis
The lack of clinical symptoms requires the use of the
imaging. Most pancreatic metastases are discovered on
a CT examination performed during the follow-up of
patients with history of primary malignancy [41].
The introduction of contrast-enhanced ultrasonography
(CEUS) has improved the diagnostic capabilities of US
[42]. In the last decade new diagnostic possibilities for
tumors of the pancreas derive from the FDG-PET/CT
[43]. Although its role in the diagnostic management of
metastases to the pancreas is not well-defined, PET ap-
pears particularly useful to exclude other metastatic sites.However, the FDG-PET/CT is not able in the evaluation
of the surgical resectability of malignant lesions.
In most cases the diagnosis of secondary pancreatic
tumors along with the differential diagnosis of primary
pancreatic adenocarcinomas can still be difficult. Many
studies suggest the possibility of a fine-needle biopsy to
establish the pathological diagnosis, although some phy-
sicians believe that this procedure should be avoided in
cases of resettable pancreatic masses. The use of im-
munocytochemistry, when available, may be useful to
confirm a suspected diagnosis [44-46].
In selected patients with pancreatic metastases, surgi-
cal resection can be considered the standard of care and
may largely ameliorate the survival of the patients. Data
from the literature indicate that an improved survival
can be achieved in patients with renal, breast, and colon
carcinomas and sarcomas as primary malignancy, while
patients with melanoma and lung cancer are related with
a poor outcome and should be treated non-operatively
[47-49]. Even in patients not amenable to surgery, a de-
finitive tissue diagnosis can be helpful in evaluating the
possibility and type of chemotherapy. In these cases and
in controversial diagnostic cases, CT can be considered
as an important tool in providing guidance in order to
obtain a definitive tissue diagnosis [50-52].
Immunohistochemistry (IHC) has a key role in the
diagnosis of mammary disease and also to discriminate
metastatic breast cancer from primary pancreatic carcin-
oma [53-56]. Differences in Cytokeratin (CK) profile
and molecular weight may aid to distinguish ductal
from lobular carcinomas [57-60], in primary as in meta-
static sites.

























Akashi [15] 15 1 (lobular) 47 41 NR Head of pancreas Solitary Pancreaticoduodenectomy 28
Bonapasta [16] 1 1 (ductal) 51 24 Jaundice,
pain
Head of pancreas Solitary Cephalic
pancreaticoduodenectomy
36
Azzarelli [17] 1 1 (lobular) 49 43 Jaundice Head of pancreas Solitary Pancreaticoduodenectomy, RT 72
Bednar [18] 2 1 (lobular) 75 96 Jaundice,
pain
Head of pancreas Solitary Pancreaticoduodenectomy 48







Crippa [19] 13 1 (lobular) 46 60 Jaundice Head of pancreas Solitary Pylorus preserving
pancreaticoduodenectomy
22
1 (lobular) 70 36 Jaundice,
pain
Head of pancreas Solitary Pylorus preserving
pancreaticoduodenectomy
38
1 (lobular) 57 84 Jaundice,
pain
Head of pancreas Solitary Pylorus preserving
pancreaticoduodenectomy
26
Dar [20] 5 1(ductal) 76 108 NR Pancreas, liver Widespread
disease
Palliative bypass 6
Engel [21] 1 1 (signet-ring cells) 59 46 Pruritis, dark
urine
Head of pancreas Solitary By-pass, CHT 15
Kitamura [22] 1 1 (ductal) 55 117 Jaundice Head of pancreas Solitary Percutaneous
transhepaticcholangio-drainage
1
Le Borgne [23] 12 1 (lobular) 48 Synchronous Jaundice Head of pancreas Solitary Pancreaticoduodenectomy, CHT 12
Mehta [24] 1 1 (comedo type) 30 36 Jaundice,
pruritis
Head of pancreas Solitary Pancreaticoduodenectomy, CHT,
HT
27
Mountney [25] 1 1 (lobular) 57 16 Jaundice Head of pancreas Solitary By-pass, HT 24
Moussa [26] 22 1 (ductal) 53 132 Acute
pancreatitis
Head of pancreas Solitary RT, CHT, HT 50
1 (lobular) 35 45 Abdominal
mass
Body of pancreas Solitary Total pancreatectomy, CHT 7
Nomizu [27] 1 1 (lobular) 46 80 Jaundice Head of pancreas Solitary Pancreaticoduodenectomy,
CHT, HT
18
Pan [28] 6 1 (lobular) 59 182 Jaundice Head of pancreas Solitary CHT, HT 21
























Table 1 Clinical features of the patients with pancreatic metastases from primary breast cancer (Continued)
Pérez Ochoa [30] 2 1 (lobular) 60 1 Jaundice Head of pancreas, Widespread
disease
Biliary stent, cephalic 2
Bone Pancreaticoduodenectomy, CHT
1 (ductal) 55 108 None Tail of pancreas Solitary Distal pancreatectomy,
splenectomy, CHT
2
Tohnosu [31] 1 1 (scirrhous type) 54 52 None Tail of pancreas Solitary Distal pancreatectomy, CHT, HT 5
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press hormone receptors (HRs), the estrogen receptor
(ER), and/or the progesterone receptor (PgR). In a large
study of 5,993 breast cancers, the positive rate for ER was
noted to correlate with nuclear grade of the tumor [61].
Mammaglobin is a recently described marker of breast
differentiation [62-64]: its expression has been reported
in 70% to 80% of primary and metastatic breast tumors
and overexpression in breast cancer tissues is associated
with an unfavorable prognosis [65]. Moreover, because
its expression is not altered at the metastatic site, mam-
maglobin may aid in the identification of breast carcin-
omas presenting in metastatic spread [62,66], while
changes in ER, PgR, and HER2 status have been de-
scribed in a significant number of patients over the
course of disease progression [67].
Treatment
The vast majority of metastatic breast cancers are incur-
able; hence, the primary goals of systemic treatment are
prolongation of survival, alleviation of symptoms, and
maintenance or improvement in quality of life [68,69].
In HR-positive and HER-2-negative disease, endocrine
therapy is the treatment of first choice independent of
metastatic site, unless rapid response is needed. Limited
visceral metastases are not a contraindication for endo-
crine therapy. The choice of endocrine agent should be
based on menopausal status, co-morbidities, agents
received in the adjuvant setting, and the drug safety
profile. If the disease progresses rapidly (within a few
months) following initiation of first-line endocrine
therapy, chemotherapy is generally recommended as a
second-line. After chemotherapy response stabilizes
(usually 4 to 6 months), a maintenance endocrine ther-
apy can be considered [70].
Surgery can be considered a first choice of treatment
not only to differentiate between metastasis and primary
pancreatic carcinoma, but also to enable survival given
the improved outcome with pancreatic resection in re-
cent decades [71,72]. Resections of pancreatic metastasis
account for less than 5% of all pancreatic resections [73];
in fact, only few patients with isolated disease to the
pancreas should be considered for surgical resection.
Several studies [11] have demonstrated that the resec-
tion of both pancreatic and limited extrapancreatic mass
can be performed with low risk for the patient, as con-
firmed by our case. Although the role of pancreatico-
duodenectomy is not clearly defined in the management
of metastatic lesions, it seems to be associated with im-
proved survival and useful palliation. Therefore the re-
section of an isolated metastasis to the pancreas seems
to be an advantageous element for prognosis respect to
the resection of a primary tumor of the pancreas, with a
5-year survival rate of 15% to 20% compared to amedian survival after successful resection of approxi-
mately 12- to 19 months, respectively [12].
Conclusion
We described a very rare case of a patient with primary
breast cancer and a misdiagnosed synchronous primary
carcinoma of the duodenal papilla. After the preoperative
diagnosis, our patient was treated with a surgical approach.
On the basis of the preoperative findings, we performed a
pancreaticoduodenectomy followed by a mastectomy to
treat two synchronous primary cancers. Only subsequent
pathological examinations of surgical specimens revealed
that the finding in the pancreas and duodenum was actu-
ally a solitary metastasis by a lobular breast cancer.
The peculiarity of our report is that it is one of the
few cases published in the literature of an isolated and
synchronous pancreatic metastasis from breast cancer.
Usually, the interval time from first diagnosis and recur-
rence varies from a few months to several years, and
synchronous presentation is an extremely rare event.
Table 1 shows the clinical features of the patients
with pancreatic metastases from different malignancies.
Among those, 23 patients exhibited metastatic involve-
ment of the pancreas from primary breast cancer, but in
19 of these patients the metastasis was a solitary second-
ary lesion, without widespread disease, becoming evident
several months after the primary. Only in one case,
interestingly, a solitary pancreatic metastasis became evi-
dent together with the primary breast cancer, that is to
say ‘synchronous’; therefore, our case seems to be the
second reported in the literature.
The analysis of the current data shows that a radical
surgery of both primary malignancy and its metastasis is
a possible therapeutic approach for breast carcinoma as-
sociated to an isolated pancreatic metastasis, although in
most cases clinical presentation of pancreatic lesions oc-
curs only when the primary disease is in advanced stage.
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